Patent intelligence · US
US 12128034
Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof
Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof
Patent details — US 12128034
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 29, 2024
- Expiration
- Oct 24, 2044
- Claims
- 16
- CPC classes
- A61K, A61K31/18, A61K31/19, A61K31/245
Quick answer
US 12128034 (Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof) is held by Iterum Therapeutics International Limited. Status: granted. Granted Oct 29, 2024. Expires Oct 24, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/18, A61K31/19, A61K31/245, A61K31/431, A61K9/0019
More from Iterum Therapeutics International Limited
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12128034?
US 12128034 (Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof) is held by Iterum Therapeutics International Limited. Status: granted. Granted Oct 29, 2024. Expires Oct 24, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12128034?
Iterum Therapeutics International Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 12128034 expire?
Our index shows an expiration date of Oct 24, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.